Conference
Cost-Effectiveness of SABR in Oligometastatic Cancer: An Economic Analysis Based on Long-Term Results of the SABR-COMET Trial
Abstract
Purpose/Objective(s) Our published economic analysis of the SABR-COMET randomized trial determined that SABR is cost-effective for patients with 1-5 oligometastases, with incremental cost-effectiveness ratios (ICERs) of $37,157 (2018 CAD$) and $54,564 (2018 USD$) for the Canadian and American health care systems, respectively. Long-term outcomes from SABR-COMET, with a median follow-up of 51 months, are now available. The aim of this study is …
Authors
Qu MX; Chen Y; Zaric G; Senan S; Olson RA; Harrow S; John-Baptiste A; Gaede S; Mulroy L; Schellenberg D
Volume
111
Publisher
Elsevier
Publication Date
November 2021
DOI
10.1016/j.ijrobp.2021.07.1038
Conference proceedings
International Journal of Radiation Oncology • Biology • Physics
Issue
3
ISSN
0360-3016